{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sang L"],"funding":["111 Incubation Project","Major Discipline Academic and Technical Leaders Training Program of Jiangxi Province","National Natural Science Foundation of China"],"pagination":["247-262"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10879352"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(2)"],"pubmed_abstract":["<h4>Objective</h4>Antineoplastic agent-induced systolic dysfunction is a major reason for interruption of anticancer treatment. Although targeted anticancer agents infrequently cause systolic dysfunction, their combinations with chemotherapies remarkably increase the incidence. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a potent in vitro model to assess cardiovascular safety. However, quantitatively predicting the reduction of ejection fraction based on hiPSC-CMs is challenging due to the absence of the body's regulatory response to cardiomyocyte injury.<h4>Methods</h4>Here, we developed and validated an in vitro-in vivo translational platform to assess the reduction of ejection fraction induced by antineoplastic drugs based on hiPSC-CMs. The translation"],"journal":["Pharmaceutical research"],"pubmed_title":["An In Silico Platform to Predict Cardiotoxicity Risk of Anti-tumor Drug Combination with hiPSC-CMs Based In Vitro Study."],"pmcid":["PMC10879352"],"funding_grant_id":["20212BCJ23025","81973391","BC2018024","81773826"],"pubmed_authors":["Qian H","Hao K","Zhang Y","He H","Luo S","Zhou Y","Sang L","Zhou Z"],"additional_accession":[]},"is_claimable":false,"name":"An In Silico Platform to Predict Cardiotoxicity Risk of Anti-tumor Drug Combination with hiPSC-CMs Based In Vitro Study.","description":"<h4>Objective</h4>Antineoplastic agent-induced systolic dysfunction is a major reason for interruption of anticancer treatment. Although targeted anticancer agents infrequently cause systolic dysfunction, their combinations with chemotherapies remarkably increase the incidence. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a potent in vitro model to assess cardiovascular safety. However, quantitatively predicting the reduction of ejection fraction based on hiPSC-CMs is challenging due to the absence of the body's regulatory response to cardiomyocyte injury.<h4>Methods</h4>Here, we developed and validated an in vitro-in vivo translational platform to assess the reduction of ejection fraction induced by antineoplastic drugs based on hiPSC-CMs. The translation","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-06-10T09:25:12.701Z","creation":"2025-04-06T12:32:42.61Z"},"accession":"S-EPMC10879352","cross_references":{"pubmed":["38148384"],"doi":["10.1007/s11095-023-03644-4"]}}